Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa

Int J Dermatol. 2023 Dec;62(12):1543-1544. doi: 10.1111/ijd.16892. Epub 2023 Oct 28.

Authors

Tanya Henry¹, Brian Cahn², Roger Haber², John T Landers³, Reed Berger-Fleishman⁴, Murad Alam⁵, Sheryl Hoyer²

Affiliations

¹ University of Illinois, College of Medicine, Chicago, IL, USA.
² Department of Dermatology, University of Illinois, Chicago, IL, USA.
³ Lovell Federal Health Care Center, North Chicago, IL, USA.
⁴ Department of Bariatric Surgery, University of Illinois, Chicago, IL, USA.
⁵ Department of Dermatology, Northwestern Medicine, Chicago, Illinois, USA.

PMID: 37897079
DOI: 10.1111/ijd.16892

No abstract available

MeSH terms

Glucagon-Like Peptide 1* / therapeutic use
Glucagon-Like Peptide-1 Receptor* / agonists
Hidradenitis Suppurativa* / drug therapy
Humans

Substances

Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor